Literature DB >> 16288375

In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.

Gustaf Ahlen1, Jessica Nystrom, Irmgard Pult, Lars Frelin, Catharina Hultgren, Matti Sallberg.   

Abstract

A key question in the development of a therapeutic vaccine against hepatitis C virus (HCV) is whether vaccine-primed T cells enter the liver and eliminate HCV-expressing hepatocytes. In the absence of an infectious small-animal model, we evaluated liver homing of vaccine-primed T cells in mice with transient hepatic transgene expression of the HCV nonstructural 3/4A (NS3/4A) protein. We found that T cells primed by transdermal DNA-based vaccination entered the liver and cleared NS3/4A-expressing hepatocytes in transiently transgenic CD8(+/+) mice but not in CD8(-/-) mice. Hence, peripherally primed NS3/4A-specific CD8(+) T cells home to the liver and clear HCV protein-expressing hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288375     DOI: 10.1086/498218

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Peripheral immunization induces functional intrahepatic hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver.

Authors:  Krystle A Lang Kuhs; Roberta Toporovski; Arielle A Ginsberg; Abby L Olsen; Devon J Shedlock; Matthew P Morrow; Jian Yan; Rebecca G Wells; David B Weiner
Journal:  Hum Vaccin       Date:  2011-12-01

2.  Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.

Authors:  N Obeng-Adjei; D K Choo; J Saini; J Yan; P Pankhong; A Parikh; J S Chu; D B Weiner
Journal:  Cancer Gene Ther       Date:  2012-10-05       Impact factor: 5.987

Review 3.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 4.  A new insight into hepatitis C vaccine development.

Authors:  Chun I Yu; Bor-Luen Chiang
Journal:  J Biomed Biotechnol       Date:  2010-06-13

5.  Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity.

Authors:  Malihe Naderi; Atefeh Saeedi; Abdolvahab Moradi; Mishar Kleshadi; Mohammad Reza Zolfaghari; Ali Gorji; Amir Ghaemi
Journal:  Virol Sin       Date:  2013-05-25       Impact factor: 4.327

Review 6.  Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies?

Authors:  Ivan Rusyn; Stanley M Lemon
Journal:  Cancer Lett       Date:  2013-07-18       Impact factor: 8.679

Review 7.  Treatment of hepatitis C virus infection.

Authors:  Kilian Weigand; Wolfgang Stremmel; Jens Encke
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

8.  The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease.

Authors:  L Frelin; E D Brenndörfer; G Ahlén; M Weiland; C Hultgren; M Alheim; H Glaumann; B Rozell; D R Milich; J G Bode; M Sällberg
Journal:  Gut       Date:  2006-03-09       Impact factor: 23.059

Review 9.  Status of hepatitis C virus vaccination: Recent update.

Authors:  Kouka Saadeldin Abdelwahab; Zeinab Nabil Ahmed Said
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

10.  Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Authors:  G Ahlén; E Derk; M Weiland; J Jiao; N Rahbin; S Aleman; D L Peterson; K Pokrovskaja; D Grandér; L Frelin; M Sällberg
Journal:  Gut       Date:  2008-08-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.